ERBB2 and neoplasm: This has led to the approval of many drugs capable to target specific molecular alterations in a certain tumor, e.g., gefitinib in EGFR-mutated non-small cell lung cancer [1] or trastuzumab in HER2-amplified or overexpressed breast cancer [2].